TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12153067

Group type: EXPERIMENTAL
Intervention: Recoded ICD‐9‐CM data
Number of subjects: 991

Group type: COMPARATOR
Intervention: Hospital‐reported ICD‐9‐CM data
Number of subjects: 991
Study: 10408488

Group type: EXPERIMENTAL
Intervention: P. acnes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: M. tuberculosis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: P. granulosum
Number of subjects: 15
Study: 8979541

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 0
Study: 1447645

Group type: EXPERIMENTAL
Intervention: DTP‐Ac vaccine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 162
Study: 3882109

Group type: EXPERIMENTAL
Intervention: Hyoscine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30904691

Group type: EXPERIMENTAL
Intervention: Real-TNS (transcutaneous trigeminal nerve stimulation)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham-TNS (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS)
Number of subjects: 29
Study: 30152167

Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization procedure based on Mann-Whitney U test statistic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed procedure
Number of subjects: 0
Study: 26667034

Group type: EXPERIMENTAL
Intervention: Cannabis (450 μg/kg THC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cocaine HCl (300 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cannabis and Cocaine
Number of subjects: 122
Study: 24767620

Group type: EXPERIMENTAL
Intervention: CI Compassionate Goals
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CI Coping
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard TSST instructions (SI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard instructions with access to 'control' (SI Control)
Number of subjects: 54
Study: 23106987

Group type: EXPERIMENTAL
Intervention: Unimanual constraint‐induced movement therapy (CIMT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hand‐arm bimanual intensive training (HABIT)
Number of subjects: 16
Study: 20600472

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (15 Hz)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study: 18046973

Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg once daily (titration 60 mg od)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily (titration 100 mg od)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Home BP assessments
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Adverse events related to study medications
Number of subjects: 375
Study: 16128599

Group type: EXPERIMENTAL
Intervention: MF 5232 (Mucotrol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12522468

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 441

Group type: COMPARATOR
Intervention: perindopril 4 mg
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: SBPM
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: office hypertension
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: home hypertension
Number of subjects: 441
Study: 10547552

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (50 mg every other day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 8697725

Group type: EXPERIMENTAL
Intervention: ELAT
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Tube DAT
Number of subjects: 147

Group type: COMPARATOR
Intervention: Gel-DAT
Number of subjects: 147
Study: 1576632

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Clindamycin and aminoglycoside (C+A)
Number of subjects: 117
Study: 6203312

Group type: EXPERIMENTAL
Intervention: Short term anthralin application schedule
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Anthralin treatment once or twice a week after healing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Anthralin treatment combined with UV irradiation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Anthralin treatment
Number of subjects: 63
Study: 30461111

Group type: EXPERIMENTAL
Intervention: Care as usual plus SOS training (n = 125)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Care as usual (n = 125)
Number of subjects: 250
Study: 29513699

Group type: EXPERIMENTAL
Intervention: Open-label placebos without deception
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inducing positive expectations about the placebo effect
Number of subjects: 46

Group type: COMPARATOR
Intervention: No pills at all (Control)
Number of subjects: 46
Study: 26391889

Group type: EXPERIMENTAL
Intervention: SKILLS intervention
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: ENGAGE intervention
Number of subjects: 137
Study: 25269854

Group type: EXPERIMENTAL
Intervention: Olopatadine HCl ophthalmic solution 0.1%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epinastine HCl ophthalmic solution 0.05%
Number of subjects: 50
Study: 22101494

Group type: EXPERIMENTAL
Intervention: Standardised stress‐induction protocol (Trier Social Stress Test)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standardised control situation
Number of subjects: 48
Study: 20560910

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for cockroach
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for dust mite
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for mouse
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for cat
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Higher cat, dust mite, and mouse allergen-specific IgE levels
Number of subjects: 546
Study: 16928710

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 16236859

Group type: EXPERIMENTAL
Intervention: Aminophylline 225 mg bid po for 8 weeks (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aminophylline 225 mg bid po for 8 weeks (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aminophylline 225 mg bid po for 8 weeks (both groups)
Number of subjects: 60
Study: 12398955

Group type: EXPERIMENTAL
Intervention: TIMI risk score (scores 0 to 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMI risk score (score 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMI risk score (score 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMI risk score (scores 5 to 7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative strategy (TIMI score 0 to 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative strategy (TIMI score >= 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMI risk score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative group
Number of subjects: 0
Study: 9933750

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) 2 g/day for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Linoleic acid (LA) 2 g/day for 6 weeks
Number of subjects: 16
Study: 7551880

Group type: EXPERIMENTAL
Intervention: DAN-PSS-1 system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-blocker treatment
Number of subjects: 0
Study: 2186867

Group type: EXPERIMENTAL
Intervention: Pharmacologic therapies (e.g., low-dose diuretics such as Chlorthalidone, 12.5 or 25 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpharmacologic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other agents (beta-blockers, reserpine, ACE inhibitors, calcium channel blockers)
Number of subjects: 0
Study: 355960

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous carbenicillin (administered preoperatively and continued for 24 hours)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (control)
Number of subjects: 99
Study: 31959176

Group type: EXPERIMENTAL
Intervention: Medically-tailored meals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medically-tailored meals combined with diabetes self-management education or lifestyle interventions
Number of subjects: 20
Study: 31009738

Group type: EXPERIMENTAL
Intervention: Participants with TB‐IRIS (n = 26)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Participants without TB‐IRIS (n = 22)
Number of subjects: 48
Study: 28705307

Group type: EXPERIMENTAL
Intervention: Tracheal vibration method (using Yourtone® applied to the cervical trachea for up to 5 minutes)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acapella method (a current oscillation device)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 12
Study: 25887344

Group type: EXPERIMENTAL
Intervention: Primaquine combined with dihydroartemisinin-piperaquine (three different single doses)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine alone (control group)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Direct membrane feeding experiments
Number of subjects: 1200
Study: 24005210

Group type: EXPERIMENTAL
Intervention: E-learning module plus textbook
Number of subjects: 28

Group type: COMPARATOR
Intervention: Textbook only (control group)
Number of subjects: 28
Study: 20004499

Group type: EXPERIMENTAL
Intervention: Estrogen treatment for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 43
Study: 19880890

Group type: EXPERIMENTAL
Intervention: Medial opening-wedge high tibial osteotomy fixed by TomoFix plates
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lateral closing-wedge high tibial osteotomy fixed by TomoFix plates
Number of subjects: 42
Study: 16395699

Group type: EXPERIMENTAL
Intervention: Tea drinkers (defined as those who consumed at least 1 cup of tea per day for at least 6 months)
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Tea drinkers (men)
Number of subjects: 2623

Group type: COMPARATOR
Intervention: Controls (non-tea drinkers)
Number of subjects: 2623
Study: 15589857

Group type: EXPERIMENTAL
Intervention: HMR 3339 (10 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HMR 3339 (50 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HMR 3339 (2.5 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 11320497

Group type: EXPERIMENTAL
Intervention: Conductivity kinetic model in paired filtration dialysis (PFD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium kinetic model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conductivity kinetic model
Number of subjects: 0
Study: 9207647

Group type: EXPERIMENTAL
Intervention: Monophasic defibrillation thresholds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biphasic defibrillation thresholds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shock impedance
Number of subjects: 24
Study: 7915625

Group type: EXPERIMENTAL
Intervention: Chronic beta‐adrenergic blocking therapy (study group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No beta‐blocking therapy (control group)
Number of subjects: 40
Study: 3120485

Group type: EXPERIMENTAL
Intervention: Ro15‐1788
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 28698916

Group type: EXPERIMENTAL
Intervention: SQ‐LNS during pregnancy and for 6 months postpartum
Number of subjects: 1151

Group type: COMPARATOR
Intervention: IFA during pregnancy only
Number of subjects: 1151

Group type: COMPARATOR
Intervention: MMN during pregnancy and for 6 months postpartum
Number of subjects: 1151
Study: 27446944

Group type: EXPERIMENTAL
Intervention: 3D printing assisted‐design operation (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No 3D printing assisted‐design (Group B)
Number of subjects: 30
Study: 25673568

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymorphisms in SLCO1B1 and ABCG2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wild-type alleles for SLCO1B1 and ABCG2
Number of subjects: 0
Study: 24119202

Group type: EXPERIMENTAL
Intervention: Bixalomer (BXL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (not treated with sevelamer hydrochloride)
Number of subjects: 28
Study: 19436941

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 4995

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4995
Study: 18541123

Group type: EXPERIMENTAL
Intervention: Liraglutide (5-25 microg/kg, s.c. abdomen, morning)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16316966

Group type: EXPERIMENTAL
Intervention: Bare-metal stenting
Number of subjects: 220

Group type: COMPARATOR
Intervention: Minimally invasive bypass surgery
Number of subjects: 220
Study: 12550805

Group type: EXPERIMENTAL
Intervention: Diskus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 45
Study: 10510104

Group type: EXPERIMENTAL
Intervention: J stent inserted before extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 400

Group type: COMPARATOR
Intervention: No J stent inserted before extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: J stent inserted before ESWL
Number of subjects: 400

Group type: COMPARATOR
Intervention: No J stent inserted before ESWL
Number of subjects: 400
Study: 8815556

Group type: EXPERIMENTAL
Intervention: Mepartricin at a dose of 150,000 U, administered once a day in the evening for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1716079

Group type: EXPERIMENTAL
Intervention: Cell separator
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (neurosurgery)
Number of subjects: 30
Study: 6524275

Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone and/or metamizol (IM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intercostal block with 0.5% bupivacaine (IC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg (EM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: i.v. infusion of fentanyl 0.54‐0.99 micrograms min‐1 + on-demand boluses of 7.2‐13.5 micrograms (ODAC)
Number of subjects: 80
Study: 30969976

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 137
Study: 28265180

Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a treadmill initiated 72 hours after admission
Number of subjects: 11
Study: 27129139

Group type: EXPERIMENTAL
Intervention: Music therapy performed twice a week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 24
Study: 25112009

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 microg x kg(‐1) x h(‐1)) and remifentanil (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Local anesthesia by lidocaine (1%) combined with midazolam (0.04 mg/kg) intravenous sedation
Number of subjects: 50
Study: 21567655

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 0
Study: 19618315

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d combined with aspirin 100 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuation of aspirin 100 mg/d
Number of subjects: 60
Study: 19332730

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Gefitinib 250 mg
Number of subjects: 168
Study: 16115690

Group type: EXPERIMENTAL
Intervention: Investigator's Assessment Questionnaire (IAQ)
Number of subjects: 300
Study: 12106935

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally twice daily) with 0.45% saline intravenously (group A)
Number of subjects: 183

Group type: COMPARATOR
Intervention: 0.45% saline intravenously alone (group B)
Number of subjects: 183
Study: 10433420

Group type: EXPERIMENTAL
Intervention: Soft surface (ksurf = 21.3 kN m(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hard surface (ksurf = 533 kN m(‐1))
Number of subjects: 6
Study: 7674203

Group type: EXPERIMENTAL
Intervention: Muscle splitting incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Muscle dividing incision
Number of subjects: 0
Study: 2206783

Group type: EXPERIMENTAL
Intervention: Enalapril 10‐40 mg once daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nifedipine retard 10‐40 mg twice daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5‐50 mg once daily (added for inadequate responders)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 128
Study: 7328680

Group type: EXPERIMENTAL
Intervention: Self-report of arousal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Genital pulse amplitude
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Time above a criterion level of increased vasocongestion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erotic tape recordings
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fantasy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Luteal phase of the menstrual cycle
Number of subjects: 30
Study: 31930892

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Shaoze (SI 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (Electroacupuncture at Shangyang (LI 1))
Number of subjects: 62
Study: 30744606

Group type: EXPERIMENTAL
Intervention: Physical activity intervention with health coaching and mobile health support (including a physical activity information booklet, one face-to-face session, and 12 telephone sessions, supported by an internet-based application and an activity tracker).
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (physical activity information booklet and advice to stay active).
Number of subjects: 68
Study: 28444355

Group type: EXPERIMENTAL
Intervention: Very low calorie diet with regular review (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (n = 30)
Number of subjects: 60
Study: 27611077

Group type: EXPERIMENTAL
Intervention: Brincidofovir 200 mg loading dose on day 0, followed by 100 mg on days 3, 7, 10, and 14 (bodyweight-adjusted for patients <50 kg).
Number of subjects: 4
Study: 24414742

Group type: EXPERIMENTAL
Intervention: Noise protection group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 21926599

Group type: EXPERIMENTAL
Intervention: Insulin infusion for blood glucose control to 80-110 mg/dL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional glucose management (insulin administered only when glucose levels rose above 215 mg/dL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 19950091

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 47
Study: 17323226

Group type: EXPERIMENTAL
Intervention: P300 evoked potential in SD patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control group (25 individuals)
Number of subjects: 25
Study: 15310081

Group type: EXPERIMENTAL
Intervention: Losartan 50 to 100 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valsartan 80 to 160 mg/d
Number of subjects: 30
Study: 11557917

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 596
Study: 9753850

Group type: EXPERIMENTAL
Intervention: Serum tocopherols levels in coronary artery disease patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study: 7811043

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (528 mg, 30 ml of Pepto-Bismol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg)
Number of subjects: 12
Study: 3290706

Group type: EXPERIMENTAL
Intervention: CR4-Sinemet (twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CR4-Sinemet
Number of subjects: 36
Study: 16225491

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subjects with gastro-oesophageal reflux disease
Number of subjects: 10
Study: 31241510

Group type: EXPERIMENTAL
Intervention: HIV Stigma-reduction through Education, Empowerment, and Research (SEERs) Project
Number of subjects: 641
Study: 28650919

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 25648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25648

Group type: EXPERIMENTAL
Intervention: HYSUD model
Number of subjects: 25648
Study: 25382074

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (IVBI) 1.25 mg at baseline and pro re nata based on ME presence; follow-up for 12 months.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Subthreshold grid laser treatment (SGLT) administered once; follow-up for 12 months.
Number of subjects: 35
Study: 23441791

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser assisted pocket therapy (ELAPT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both treatments (ELAPT and OFD)
Number of subjects: 15
Study: 21855969

Group type: EXPERIMENTAL
Intervention: Propiverine treatment
Number of subjects: 282